Literature DB >> 10871765

Biphasic and regionally-restricted chemokine expression in the central nervous system in the Theiler's virus model of multiple sclerosis.

P D Murray1, K Krivacic, A Chernosky, T Wei, R M Ransohoff, M Rodriguez.   

Abstract

Intracerebral infection of susceptible strains of mice with Theiler's murine encephalomyelitis virus (TMEV) induces a biphasic disease characterized by acute polioencephalitis followed by chronic demyelination and viral persistence in the spinal cord white matter. There has been limited study of soluble mediators responsible for the initial recruitment of inflammatory cells into the gray matter, and the secondary influx into the white matter during infection with TMEV. We used sensitive and specific RT - PCR/dot blot hybridization assays to quantitate the relative levels of chemokine mRNA in the brains and spinal cords during the acute and chronic phases of TMEV infection in mice susceptible (B10.M, H-2f) and resistant (B10, H-2b) to virus-induced demyelination. TMEV infection resulted in robust expression of mRNA for IP-10, RANTES, and MCP-1, but not GRO-alpha, in brains and spinal cords in both strains of mice within 5 days. By day 21, virus was cleared, inflammation reduced, and expression of all three chemokines subsided to baseline levels in the brains and spinal cords of resistant mice, and the brains of susceptible mice. Chemokine expression was also reduced in the spinal cords of susceptible mice, corresponding to a shift in TMEV replication from the gray to the white matter. During the chronic, demyelinating phase of infection, there was a resurgence in IP-10, RANTES, and MCP-1 mRNA in spinal cords of susceptible B10.M mice. This study demonstrates the coordinated regulation and regionally restricted expression of chemokines in a biphasic disease of the central nervous system and provides greater understanding of the mechanism by which inflammation is established and maintained in the CNS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871765

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  15 in total

Review 1.  Chemokines and central nervous system disorders.

Authors:  W J Karpus
Journal:  J Neurovirol       Date:  2001-12       Impact factor: 2.643

2.  Anti-CCL2 treatment inhibits Theiler's murine encephalomyelitis virus-induced demyelinating disease.

Authors:  William J Karpus; Kevin J Kennedy; Brian T Fife; Jamie L Bennett; Mauro C Dal Canto; Steven L Kunkel; Nicholas W Lukacs
Journal:  J Neurovirol       Date:  2006-08       Impact factor: 2.643

3.  A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis.

Authors:  Aitor G Granja; Francisco Carrillo-Salinas; Alberto Pagani; María Gómez-Cañas; Roberto Negri; Carmen Navarrete; Miriam Mecha; Leyre Mestre; Bend L Fiebich; Irene Cantarero; Marco A Calzado; Maria L Bellido; Javier Fernandez-Ruiz; Giovanni Appendino; Carmen Guaza; Eduardo Muñoz
Journal:  J Neuroimmune Pharmacol       Date:  2012-09-14       Impact factor: 4.147

4.  Transition from acute to persistent Theiler's virus infection requires active viral replication that drives proinflammatory cytokine expression and chronic demyelinating disease.

Authors:  Mark Trottier; Brian P Schlitt; Aisha Y Kung; Howard L Lipton
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

5.  CXCL10 production from cytomegalovirus-stimulated microglia is regulated by both human and viral interleukin-10.

Authors:  Maxim C-J Cheeran; Shuxian Hu; Wen S Sheng; Phillip K Peterson; James R Lokensgard
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  Interleukin-6, produced by resident cells of the central nervous system and infiltrating cells, contributes to the development of seizures following viral infection.

Authors:  Jane E Libbey; Nikki J Kennett; Karen S Wilcox; H Steve White; Robert S Fujinami
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

7.  Interleukin-6 protects anterior horn neurons from lethal virus-induced injury.

Authors:  Kevin D Pavelko; Charles L Howe; Kristen M Drescher; Jeff D Gamez; Aaron J Johnson; Tao Wei; Richard M Ransohoff; Moses Rodriguez
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

Review 8.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

Review 9.  Astrocytes in multiple sclerosis: a product of their environment.

Authors:  A Nair; T J Frederick; S D Miller
Journal:  Cell Mol Life Sci       Date:  2008-09       Impact factor: 9.261

10.  The immune response in the CNS in Theiler's virus induced demyelinating disease switches from an early adaptive response to a chronic innate-like response.

Authors:  Francesca Gilli; Libin Li; Andrew R Pachner
Journal:  J Neurovirol       Date:  2015-08-11       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.